Granules India announced that the US Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for glycopyrrolate oral solution 1mg/5mL filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the company.
It is bioequivalent and therapeutically equivalent to the reference listed drug, Cuvposa oral solution, 1 mg/5 mL of Merz Pharmaceuticals, LLC.
Glycopyrrolate oral solution is an anticholinergic medication indicated for paediatric patients aged three to 16 years who have neurological conditions associated with problem drooling.
"As we strengthen Granules’ footprint in the US market, this approval highlights our robust quality systems, ensuring compliance with the highest regulatory standards," said Dr Krishna Prasad Chigurupati, chairman and managing director, Granules India Limited.
Granules India Limited, incorporated in 1991 is a vertically integrated fast-growing Indian pharmaceutical company headquartered in Hyderabad with best-in-class facilities and a commitment to operational excellence, quality, and customer service.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!